This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2040 Remove Data Remove Programs Related Topics
Clinical Trials Decriminalization Concentrates Compliance Safety Treatment Cannabinoids Conditions Policy Access More Related Topics >
article thumbnail

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update

Cannabis Law Report

NOVEMBER 12, 2021

” The patent provides protection through 2040 and describes use of the Company’s investigational drug ANEB-001 to treat acute cannabinoid overdose. In August Anebulo formed the SAB to advise the Company on its clinical development programs and product pipeline. Condensed Balance Sheet Data. . . and Arjun Chanmugam, M.D.,

Pharmaceutical 52
Pharmaceutical Clinical Trials Business Research and Development 52
article thumbnail

Schumer, Booker, Wyden Introduce Booker, Schumer, Wyden Introduce , Cannabis Administration and Opportunity Act

Cannabis Law Report

JULY 21, 2022

You might not be so excited to learn there are 296 pages of draft legislation to be read which implies to us that the amendment conversation could still be happening when Kyle Jenner is voted president in 2040. Cannabis legalization is here, and Congress needs to get with the program.” Hopefully i’ll be dead by then.

Safety 52
Safety Legislation Clinical Trials Banking 52
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 24,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024